Clinical Trials Browser

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03404960 2025-10-10

Parpvax

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT06747845 2025-09-16

ParpVax2

Phase 2 Recruiting

68 enrolled

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Phase 2 Completed

18 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Phase 2 Completed

22 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Phase 1/2 Terminated

3 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

GastrointestinalOther solid neoplasm

MMR-D/MSI-H Colorectal Cancers

NCT03840967 2024-06-04

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Phase 2 Terminated

14 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Phase 2 Completed

37 enrolled 15 charts

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

NCT05412706 2023-09-08

Bohème

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT03221400 2022-02-17

PEN-866 in Patients With Advanced Solid Malignancies

Phase 1/2 Unknown

340 enrolled

GastrointestinalThoracic

Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase 1 Unknown

52 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Clinical Trials

SAFIR-ABC10

Niraparib in Patients With Pancreatic Cancer

PARPi-PANC

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

NIPAVect

NIRADO

PAVO

Parpvax

ParpVax2

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

SMMART Adaptive Clinical Treatment (ACT) Trial

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Bohème

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

PEN-866 in Patients With Advanced Solid Malignancies

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors